Better Health for All

Citius Oncology's principal product, LYMPHIR, is an FDA-approved immunotherapy for relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL).

a rare cancer with limited treatment options. Clinical trials showed an Objective Response Rate of 36.2% and a Complete Response Rate of 8.7%, with over half of patients having responses lasting at least six months. The company's core business is focused on developing treatments for unmet medical needs in oncology and critical care, indicating a strong commitment to health-positive products. There is no evidence of revenue from products with negative health outcomes. However, LYMPHIR is associated with significant safety concerns, including a Boxed Warning for capillary leak syndrome (CLS), which occurred in 27% of patients, with one fatal case (0.8%). Other adverse events include visual impairment in 9% and infusion-related reactions in 69% of patients. The company provides detailed safety information, including the Boxed Warning, in its prescribing information. A permanent J-code (J9161) has been assigned by CMS for LYMPHIR, effective April 1, 2025, which is expected to facilitate access for patients with commercial and government insurance. Citius Oncology also mentions robust intellectual property protections for LYMPHIR, including orphan drug designation, complex technology, trade secrets, and pending patents, without evidence of flexibility for global health needs.

Fair Money & Economic Opportunity

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing critical care products. Its core business does not involve lending, deposit services, or other financial services to consumers.

Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to its operations. The available evidence discusses the company's financial performance, drug development, and the market for its therapies, but does not indicate any involvement in financial services or related initiatives for consumers.

Fair Trade & Ethical Sourcing

No specific, quantitative data related to fair trade and ethical sourcing for Citius Oncology, Inc. (CTOR.US) was found in the provided articles.

Information regarding supplier certifications, audit frequencies, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend is not available.

Kind to Animals

The provided articles do not contain specific, concrete data points for any of the 'Kind to Animals' KPIs. While one article states that Citius Pharmaceuticals Inc. engages in animal testing, it explicitly notes that no quantitative data on volume, policy, or alternative testing methods is provided.

Other articles also indicate a lack of data regarding cruelty-free certifications, humane certifications, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, R&D investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.

No War, No Weapons

Citius Oncology, Inc. is a biopharmaceutical company with no reported revenue from arms or defense contracts for fiscal years 2024 and 2025.

The company's core business is the development and commercialization of critical care products, focusing on oncology. Its AI-driven analytics are used for commercial efficiency, not for military applications. There is no evidence of sales to embargoed or sanctioned regimes, nor any involvement in intelligence or surveillance activities. The company's operations do not involve dual-use technologies with military applications, controversial weapons, or any activities that would require ethical red lines related to weapons. There is no evidence of any operations in conflict-affected areas or procurement from such regions, nor any lobbying related to arms control.

Planet-Friendly Business

The company's total Scope 1, 2, and 3 greenhouse gas emissions are 1,850 metric tons CO2e, with a target to reduce this to 1,575 metric tons CO2e by 2025.

It achieves a 68% waste diversion rate for pharmaceutical waste, and also implements specialized recycling for plastic lab waste and chemical neutralization for chemical waste.

Respect for Cultures & Communities

The provided articles focus exclusively on Citius Oncology's biopharmaceutical operations, including product development, regulatory approvals, and commercial launch plans for LYMPHIR.

There is no explicit information or data available in any of the articles regarding the company's engagement with local or indigenous communities, cultural impact assessments, community investments, local employment, grievance mechanisms, or any other metrics related to the 'Respect for Cultures & Communities' ethical value. Consequently, no KPIs can be scored based on the provided evidence.

Safe & Smart Tech

The company's privacy policy states the use of HTTPS protocol for encrypted data transmission.

It also outlines user rights under UK GDPR, including access, correction, erasure, restriction, objection, and data portability. For data minimization, the company specifies data retention periods of 5 years for basic contact data and 2 years for health-related data. The privacy policy explicitly states compliance with UK GDPR and the Data Protection Act 2018.